David A. Siegel Aadi Bioscience, Inc. Put Options Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding AADI
# of Institutions
68Shares Held
12MCall Options Held
9.4KPut Options Held
2.5K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.33 Million0.06% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.46 Million2.91% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.05 Million4.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.43 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC526KShares$984,2351.41% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $39.3M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...